JCR Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

JCR Pharmaceuticals şirketinin kazançları yıllık ortalama -0.3% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 4.3% oranında artan oldu. Gelirler yıllık ortalama 9.5% oranında artan oldu.

Anahtar bilgiler

-0.3%

Kazanç büyüme oranı

-0.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	3.4%
Gelir büyüme oranı	9.5%
Özkaynak getirisi	-0.7%
Net Marj	-1.2%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Sep 06

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

Sep 04

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Aug 23

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Aug 09

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

Aug 03

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

Jul 26

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Jul 12

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

Gelir ve Gider Dağılımı

JCR Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TSE:4552 Gelir, gider ve kazançlar (JPY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	35,256	-437	14,058	11,234
30 Jun 24	40,208	4,098	24,708	0
31 Mar 24	42,871	5,507	12,485	11,234
31 Dec 23	41,365	5,364	14,321	8,802
30 Sep 23	43,034	8,063	13,172	8,802
30 Jun 23	35,545	4,014	11,921	8,802
31 Mar 23	34,343	3,772	11,678	8,802
31 Dec 22	37,508	5,154	13,267	7,175
30 Sep 22	38,280	6,235	13,252	7,175
30 Jun 22	50,875	14,343	13,943	7,175
31 Mar 22	51,082	14,507	13,511	7,175
31 Dec 21	50,931	16,549	14,071	5,360
30 Sep 21	47,517	14,899	12,771	5,360
30 Jun 21	34,717	7,657	10,483	5,360
31 Mar 21	30,085	6,892	8,624	5,360
31 Dec 20	26,128	4,137	7,243	5,997
30 Sep 20	24,496	2,983	6,685	5,997
30 Jun 20	24,807	3,076	7,396	5,997
31 Mar 20	24,781	2,678	7,638	5,997
31 Dec 19	25,709	3,653	8,909	4,354
30 Sep 19	24,121	3,260	9,000	4,354
30 Jun 19	23,638	3,802	7,802	4,354
31 Mar 19	23,160	3,715	7,271	4,354
31 Dec 18	20,874	2,454	7,177	4,211
30 Sep 18	20,682	2,566	6,745	4,211
30 Jun 18	20,885	2,857	6,642	4,211
31 Mar 18	20,594	3,070	6,470	4,211
31 Dec 17	20,233	2,930	6,502	4,071
30 Sep 17	19,738	2,722	6,387	4,071
30 Jun 17	18,670	2,079	6,095	4,071
31 Mar 17	18,085	1,863	5,920	4,071
31 Dec 16	17,483	1,668	6,061	3,348
30 Sep 16	17,190	1,751	5,511	3,348
30 Jun 16	17,091	1,620	5,618	3,348
31 Mar 16	17,438	1,789	5,478	3,348
31 Dec 15	17,594	2,299	5,383	3,334
30 Sep 15	17,482	2,281	5,405	3,334
30 Jun 15	17,192	1,861	5,678	3,334
31 Mar 15	16,855	1,682	5,713	3,334
31 Dec 14	16,380	1,066	6,792	2,202
30 Sep 14	16,516	1,319	6,895	2,202
30 Jun 14	16,117	1,316	6,280	2,202
31 Mar 14	15,705	1,296	6,116	2,202
31 Dec 13	15,669	1,517	6,269	1,991

Kaliteli Kazançlar: 4552 şu anda kârlı değil.

Büyüyen Kar Marjı: 4552 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4552 kârlı değildir ve zararlar son 5 yılda yılda 0.3% oranında artmıştır.

Büyüme Hızlandırma: 4552 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 4552 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 12.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 4552 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -0.71% ) sahiptir.

JCR Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

Recent updates

Now 21% undervalued

New minor risk - Share price stability

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIA

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend

JCR Pharmaceuticals Co., Ltd. Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual Congress

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

What JCR Pharmaceuticals Co., Ltd.'s (TSE:4552) 32% Share Price Gain Is Not Telling You

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Investor sentiment deteriorates as stock falls 17%

Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd Announces Discontinuation of TEMCELL HS Inj. Expanded Indication Development for Neonatal Hypoxic Ischemic Encephalopathy

JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00

Final dividend of JP¥10.00 announced

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Consensus EPS estimates fall by 17%

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%